Categories Uncategorized

Could We Soon Use Apps to Know How Long We Have to Live?

Nearly everyone asks themselves a hard question on when they will die. The question prompts different answers as innovations are on the verge of bringing apps that could predict our lifespan.

However, there may be an abuse of these apps, such as invading of people’s privacy. Though as it stands, coming up with an app that will accurately predict one’s life expectancy may be difficult. Success may be halted by other factors such as the genetic composition of an individual. But with the new technology emerging, that app may be brought to reality sooner than we think.

Calculating life expectancy

Experts have been predicting the life expectancy of a population based on ethnicity and other such broad factors. However, mechanisms such as artificial intelligence and deep learning can now be employed in unravelling compound variables like biomedical information in predicting your biological age. Biological age means how old your body is rather than when you were given birth to. A reliable calculation of life expectancy will need the use of a refined structure which will put lifestyle, geographical, genetics and environmental factors into consideration.

The use of artificial intelligence and machine learning has made it achievable to analyze a huge bulk of information. Consequently, the use of cognitive computing and deep learning is helping physicians to make reliable diagnoses as compared to the use of human judgment alone. Using these systems, supported with other increasing computational powers and predictive analytics may lead to sophisticated apps that can predict your lifespan.

Is there already an app for this function?

Since there is equipment that can predict cancer survival rates, there may be other upcoming apps that may try to analyze information to predict your life expectancy. However, these apps may not be capable of giving your exact year of death. Since human activities and behaviors are hard to predict, it may be not easy to classify, measure and predict the precise life expectancy of an individual.

To accurately calculate, predict and measure the life span of an individual, it will require the right quantity and quality of available information. Much of this data, like the ethnicity, gender, age, height and weight, can be obtained from the user whose life expectancy is to be predicted. It could also be boosted with data from wearables and sensors, which could be vital in tracking blood pressure and heart rates.

Benefits of predicting life expectancy

Life span predictions can be essential to health providers, governments and individuals. Additionally, they would inform people of their health, whether it’s deteriorating or improving. It would therefore greatly encourage people to choose a healthy lifestyle.

Besides, pharmaceutical organizations could also use life expectancy information in coordinating medical campaigns. Also, the data could help the government in imposing different taxing methods depending on the life span of an individual.

Will these apps come to reality?

Scientists are tirelessly working on avenues to predict human life span accurately. Though it will require effort from data scientists, IT experts, health scientists, medical professionals and demographers. However, it will need a collection of enough data for this process to be effective. However, a lot of ethical concerns can arise since the information to be collected is highly sensitive and needs to be jealously protected.

Fortunately, companies like Predictive Oncology (NASDAQ: POAI) are spearheading the shift from generic remedies to personalized medicine, so this alone is likely to have a positive effect on patient’s life expectancy.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option

For long, researchers have posited that a link between our brain and gut contributes to…

22 hours ago

Breakthrough Treatment for Lung Cancer Uses Mitochondria to Supercharge Immune Cells

Researchers in China have discovered a way to supercharge the treatment of lung cancer by…

5 days ago

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic’s IzoView Breast CT Imaging System represents a breakthrough in dedicated breast imaging technology, addressing…

5 days ago

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma…

6 days ago

How to Rebuild Trust in the US Healthcare System

A recent survey undertaken by Gallup in 2025 found that since 2021, there has been…

6 days ago

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment…

6 days ago